<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03865615</url>
  </required_header>
  <id_info>
    <org_study_id>Oxytocin Approach</org_study_id>
    <nct_id>NCT03865615</nct_id>
  </id_info>
  <brief_title>Oxytocin on Approach Bias and Craving</brief_title>
  <official_title>The Effects of Intranasal Oxytocin on Approach Bias and Craving in Moderate to Heavy Alcohol Drinkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jennifer Mitchell</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a laboratory-based investigation of the behavioral and neural effects of&#xD;
      intranasal oxytocin on craving for alcohol and approach bias in moderate to heavy alcohol&#xD;
      using subjects. This study uses a within-subject, randomized, placebo-controlled,&#xD;
      counterbalanced, crossover design to compare the effects oxytocin and placebo. In this way,&#xD;
      all subjects will be scanned twice; once following oxytocin administration and once following&#xD;
      placebo administration, and will complete a series of behavioral tasks (both in and out of&#xD;
      the scanner) at both visits.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">April 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 20, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Within-subject, randomized, placebo-controlled, counterbalanced, crossover design.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alcohol cue craving score</measure>
    <time_frame>~ 90 minutes post study drug administration</time_frame>
    <description>Subjects will be asked to perform a standardized alcohol cue exposure paradigm and be asked to rate their subjective craving following alcohol cue presentation using a standard visual analog scale. Craving scores (ranging from 1-10 on VAS) will be compared across both the active study drug and placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Image approach task</measure>
    <time_frame>~ 90 minutes post study drug administration</time_frame>
    <description>Subjects will be asked to perform an image approach task where subjects are presented with a series of images and asked to pull or push a joystick following each presentation. Response direction and speed are recorded and compared across both the active study drug and placebo.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Alcohol Use Disorder</condition>
  <arm_group>
    <arm_group_label>Oxytocin First</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive oxytocin prior to their first scanning session, and placebo prior to their second scanning session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo First</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive placebo prior to their first scanning session, and oxytocin prior to their second scanning session.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>intranasal oxytocin 40IU/mL</description>
    <arm_group_label>Oxytocin First</arm_group_label>
    <arm_group_label>Placebo First</arm_group_label>
    <other_name>Syntocinon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Oxytocin First</arm_group_label>
    <arm_group_label>Placebo First</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteers who are 21-40 years of age&#xD;
&#xD;
          -  If female, 10 or more alcoholic drinks must be consumed weekly.&#xD;
&#xD;
          -  If male, 14 or more alcoholic drinks must be consumed weekly.&#xD;
&#xD;
          -  Meets DSM-V criteria for Alcohol Use Disorder (AUD).&#xD;
&#xD;
          -  Score 8 or greater on the Alcohol Use Disorders Identification Test (AUDIT)&#xD;
&#xD;
          -  If female, must be non-lactating, not pregnant, and using a reliable contraception&#xD;
             method (i.e. abstinence, intrauterine device [IUD], hormonal birth control, or barrier&#xD;
             method).&#xD;
&#xD;
          -  Native English speaker&#xD;
&#xD;
          -  Right handed&#xD;
&#xD;
          -  High school graduate or equivalent.&#xD;
&#xD;
          -  Able and willing to provide an informed consent.&#xD;
&#xD;
          -  Able to understand and follow the instructions of the investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Positive urine drug screen (except marijuana).&#xD;
&#xD;
          -  Using cocaine, stimulants (other than nicotine and caffeine), amphetamines,&#xD;
             hallucinogens, ecstasy, opiates, sedatives, pain pills, sleeping pills, or other&#xD;
             psychoactive drugs within 2 weeks of the start of the study (except marijuana).&#xD;
&#xD;
          -  Marijuana use more than 3 times/week.&#xD;
&#xD;
          -  Current enrollment in an alcohol, or other drug treatment program or current legal&#xD;
             problems relating to alcohol, or other drug use.&#xD;
&#xD;
          -  Currently trying to quit alcohol use.&#xD;
&#xD;
          -  History of major alcohol related complications within the preceding 2 years (liver&#xD;
             failure/cirrhosis, pancreatitis, esophageal varices, etc.).&#xD;
&#xD;
          -  Has a history of atrophic rhinitis, recurrent nose bleeds, cranial surgical&#xD;
             procedures, hypophysectomy, chronic congestion, or sinus problems.&#xD;
&#xD;
          -  Has a history of cardiac arrhythmia.&#xD;
&#xD;
          -  Clinically significant medical or psychiatric illness requiring treatment as&#xD;
             determined by screening blood tests, medical history, and/or physical exam performed&#xD;
             or reviewed by the study physician.&#xD;
&#xD;
          -  Severely low blood (&lt; 90/50) pressure or uncontrolled high blood pressure (&gt;160/100).&#xD;
&#xD;
          -  SGPT/ALT or SGOT/AST values greater than 2x upper limit of normal.&#xD;
&#xD;
          -  BAC level &gt; 0.00% at the beginning of screening visit (within margin of error of&#xD;
             detection).&#xD;
&#xD;
          -  Has a neurological dysfunction or psychiatric disorder (confirm with study physician).&#xD;
&#xD;
          -  Has a history of brain trauma (confirm with study physician).&#xD;
&#xD;
          -  Has an allergy or intolerance to oxytocin.&#xD;
&#xD;
          -  Has received an investigational drug within 30 days of Screening Visit.&#xD;
&#xD;
          -  Has any MRI scanning contraindications.&#xD;
&#xD;
          -  Has a history of claustrophobia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Mitchell, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Mitchell, PhD</last_name>
    <phone>510-985-3522</phone>
    <email>Jennifer.Mitchell@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dawn Weinstein</last_name>
    <phone>510-985-3522</phone>
    <email>Dawn.Weinstein@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94720</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jennifer Mitchell, PhD</last_name>
      <phone>510-985-3921</phone>
      <email>jennifer.mitchell@ucsf.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 21, 2018</study_first_submitted>
  <study_first_submitted_qc>March 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2019</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Jennifer Mitchell</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

